The earnings call presented a balanced view with significant focus on the promising pipeline and financial stability, though challenges in current obesity treatments and program discontinuation were noted. The outlook includes multiple upcoming clinical milestones, supporting a positive long-term perspective.

Company Guidance -

Q3 2025

During the Neumora Therapeutics Second Quarter 2025 Financial Results Conference Call, the company provided significant guidance on their strategic focus and upcoming milestones. Neumora emphasized their commitment to addressing major health challenges by advancing their industry-leading pipeline, which targets prevalent brain diseases. They highlighted the prioritization of obesity as the lead indication for their NLRP3 inhibitor, NMRA-215, noting that obesity affects over 2.5 billion people globally, a number expected to rise to 4 billion by 2035. The company aims to leverage their expertise in neuroscience to develop therapies that are efficacious and well-tolerated, potentially offering an alternative or complement to current GLP-1 medications, which have a high discontinuation rate due to adverse effects and limited long-term efficacy. Neumora plans to achieve up to six clinical data readouts in the next 18 months, with significant developments expected for NMRA-861 in schizophrenia and NMRA-511 in Alzheimer's disease agitation. Financially, the company reported a net loss reduction to $52.7 million for the quarter, with a cash position of $217.6 million, supporting operations well into 2027.

Pipeline Expansion and Prioritization

Prioritization of obesity as the lead indication for NMRA-215, a brain-penetrant NLRP3 inhibitor, with potential to improve efficacy and tolerability over current therapies.

Financial Stability

Neumora ended the quarter with $217.6 million in cash, cash equivalents, and marketable securities, with a cash runway anticipated to support operations into 2027.

Upcoming Clinical Milestones

Up to 6 clinical data readouts expected over the next 18 months, including Phase Ib data for NMRA-511 in Alzheimer's disease agitation and Phase III KOASTAL program data for navacaprant in major depressive disorder.

Progress in M4 PAM Program

Initiation of Phase I study for NMRA-861, a highly potent and selective M4 Positive Allosteric Modulator (PAM), showing robust activity and safety in preclinical studies.

Neumora Therapeutics, Inc. (NMRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NMRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	-0.33 / -	-0.45	―	―	―
Aug 06, 2025	2025 (Q2)	-0.36 / -0.33	-0.37	10.81% (+0.04)	―
May 12, 2025	2025 (Q1)	-0.37 / -0.42	-0.34	-23.53% (-0.08)	―
Mar 03, 2025	2024 (Q4)	-0.42 / -0.37	-0.71	47.89% (+0.34)	―
Nov 12, 2024	2024 (Q3)	-0.39 / -0.45	-1.14	60.53% (+0.69)	―
Aug 06, 2024	2024 (Q2)	-0.37 / -0.37	-0.278	-33.09% (-0.09)	―	―
May 07, 2024	2024 (Q1)	-0.34 / -0.34	-0.234	-45.30% (-0.11)	―	―
Mar 07, 2024	2023 (Q4)	-0.55 / -0.71	-0.185	-283.78% (-0.52)	―	―
Nov 01, 2023	2023 (Q3)	-0.35 / -1.14	-0.193	-490.67% (-0.95)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NMRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$1.59	$1.65	+3.77%
May 12, 2025	$0.69	$0.68	-1.45%
Mar 03, 2025	$1.56	$1.40	-10.26%
Nov 12, 2024	$13.64	$11.31	-17.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Neumora Therapeutics, Inc. (NMRA) report earnings?

Neumora Therapeutics, Inc. (NMRA) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is Neumora Therapeutics, Inc. (NMRA) earnings time?

Neumora Therapeutics, Inc. (NMRA) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NMRA EPS forecast?

NMRA EPS forecast for the fiscal quarter 2025 (Q3) is -0.33.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing